Search

Your search keyword '"DE FELICE, FRANCESCA"' showing total 10 results
Start Over Author "DE FELICE, FRANCESCA" Journal oncotarget
10 results on '"DE FELICE, FRANCESCA"'

2. Induction chemotherapy followed by neoadjuvant chemoradiotherapy and surgery in locally advanced rectal cancer: preliminary results of a phase II study

Author

De Felice, Francesca, primary, D’Ambrosio, Giancarlo, additional, Musio, Daniela, additional, Iafrate, Franco, additional, Benevento, Ilaria, additional, Marzo, Marco, additional, Mancini, Marialaura, additional, Urbano, Federica, additional, Iannitti, Marcella, additional, Marampon, Francesco, additional, Bulzonetti, Nadia, additional, Cortesi, Enrico, additional, and Tombolini, Vincenzo, additional

Published
2018
Full Text
View/download PDF

9. The role of radiation therapy in bone metastases management.

Author

De Felice F, Piccioli A, Musio D, and Tombolini V

Subjects
Bone Neoplasms complications, Bone Neoplasms mortality, Combined Modality Therapy, Dose Fractionation, Radiation, Humans, Odds Ratio, Palliative Care, Quality of Life, Radiotherapy adverse effects, Radiotherapy Planning, Computer-Assisted, Retreatment, Treatment Outcome, Bone Neoplasms radiotherapy, Bone Neoplasms secondary, Radiotherapy methods
Abstract

Bone metastases represent an important complication of malignant tumours. Despite improvement in surgical techniques and advances in systemic therapies, management of patients with bone metastatic disease remains a powerful cornerstone for the radiation oncologist. The primary goal of radiation therapy is to provide pain relief, preserving patient's quality of life.

Published
2017
Full Text
View/download PDF

10. Efficacy and toxicity of bevacizumab in recurrent ovarian disease: an update meta-analysis on phase III trials.

Author

Marchetti C, De Felice F, Palaia I, Musella A, Di Donato V, Gasparri ML, Musio D, Muzii L, Tombolini V, and Panici PB

Subjects
Angiogenesis Inhibitors therapeutic use, Carcinoma, Ovarian Epithelial, Clinical Trials, Phase III as Topic, Disease-Free Survival, Female, Humans, Neoplasms, Glandular and Epithelial mortality, Ovarian Neoplasms mortality, Treatment Outcome, Antineoplastic Agents therapeutic use, Bevacizumab therapeutic use, Neoplasm Recurrence, Local drug therapy, Neoplasms, Glandular and Epithelial drug therapy, Ovarian Neoplasms drug therapy
Abstract

Background: To analyze the efficacy and toxicity of bevacizumab on survival outcomes in recurrent ovarian cancer., Results: Bevacizumab was associated with significant improvement of PFS and OS compared with standard treatment with HRs of 0.53 (95% CI 0.44 - 0.63; p < 0.00001) and 0.87 (95% CI, 0.77 to 0.99; p = 0.03), respectively.Bevacizumab increased the incidence of G3/G4 hypertension (RR 19.01, 95% CI 7.77 - 46.55; p < 0.00001), proteinuria (RR 17.31, 95% CI 5.42 - 55.25; p < 0.00001), arterial thromboembolic events (ATE) (RR 4.99, 95% CI 1.29 - 19.27; p = 0.02) and bleeding (RR 3.14, 95% CI 1.35 - 7.32; p = 0.008)., Materials and Methods: Three randomized phase III trials representing 1502 patients were identified.Pooled hazard ratio (HR), odd ratio (OR), risk ratio (RR) with 95% confidence interval (CI) were calculated using fixed or random effects model., Conclusions: Adding bevacizumab to standard chemotherapy improved ORR, PFS and OS, and it had a higher, but manageable, incidence of toxicities graded 3 to 4.

Published
2016
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results